Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
127.99
-0.05 (-0.04%)
Apr 28, 2026, 2:53 PM EDT - Market open
Neurocrine Biosciences Employees
Neurocrine Biosciences had 2,000 employees as of December 31, 2025. The number of employees increased by 200 or 11.11% compared to the previous year.
Employees
2,000
Change (1Y)
200
Growth (1Y)
11.11%
Revenue / Employee
$1,430,250
Profits / Employee
$239,300
Market Cap
12.87B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,000 | 200 | 11.11% |
| Dec 31, 2024 | 1,800 | 400 | 28.57% |
| Dec 31, 2023 | 1,400 | 200 | 16.67% |
| Dec 31, 2022 | 1,200 | 300 | 33.33% |
| Dec 31, 2021 | 900 | 55 | 6.51% |
| Dec 31, 2020 | 845 | 145 | 20.71% |
| Dec 31, 2019 | 700 | 115 | 19.66% |
| Dec 31, 2018 | 585 | 185 | 46.25% |
| Dec 31, 2017 | 400 | 204 | 104.08% |
| Dec 31, 2016 | 196 | 76 | 63.33% |
| Dec 31, 2015 | 120 | 26 | 27.66% |
| Dec 31, 2014 | 94 | 13 | 16.05% |
| Dec 31, 2013 | 81 | 3 | 3.85% |
| Dec 31, 2012 | 78 | 7 | 9.86% |
| Dec 31, 2011 | 71 | 5 | 7.58% |
| Dec 31, 2010 | 66 | 1 | 1.54% |
| Dec 31, 2009 | 65 | -60 | -48.00% |
| Dec 31, 2008 | 125 | -10 | -7.41% |
| Dec 31, 2007 | 135 | -132 | -49.44% |
| Dec 31, 2006 | 267 | -321 | -54.59% |
| Dec 31, 2005 | 588 | 203 | 52.73% |
| Dec 31, 2004 | 385 | 40 | 11.59% |
| Dec 31, 2003 | 345 | 69 | 25.00% |
| Dec 31, 2002 | 276 | 54 | 24.32% |
| Dec 31, 2001 | 222 | 34 | 18.09% |
| Dec 31, 2000 | 188 | 37 | 24.50% |
| Dec 31, 1999 | 151 | 2 | 1.34% |
| Dec 31, 1998 | 149 | 41 | 37.96% |
| Dec 31, 1997 | 108 | 5 | 4.85% |
| Dec 31, 1996 | 103 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 33,950 |
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,811 |
| Haleon | 24,535 |
| Elanco Animal Health | 9,900 |
| Amneal Pharmaceuticals | 8,700 |
| Hims & Hers Health | 2,442 |
| Alkermes | 2,050 |
NBIX News
- 5 days ago - Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia - PRNewsWire
- 13 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results - PRNewsWire
- 14 days ago - Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR - PRNewsWire
- 15 days ago - Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia - GlobeNewsWire
- 21 days ago - Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - Reuters
- 22 days ago - Neurocrine Biosciences Transcript: M&A announcement - Transcripts
- 22 days ago - Neurocrine to Buy Soleno for $2.9 Billion - WSJ
- 22 days ago - This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal. - Barrons